166 related articles for article (PubMed ID: 717538)
1. Tumor immunity. An overview.
Siegel BV
Am J Pathol; 1978 Nov; 93(2):515-24. PubMed ID: 717538
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy with surgery.
Orita K; Miwa H; Mannami T; Konaga E; Yumura M
Acta Med Okayama; 1977 Aug; 31(4):217-34. PubMed ID: 145159
[TBL] [Abstract][Full Text] [Related]
3. A prospect on cancer immunology.
Kobayashi H
Hokkaido Igaku Zasshi; 1979 Nov; 54(6):549-77. PubMed ID: 397163
[TBL] [Abstract][Full Text] [Related]
4. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy.
Merritt RE; Yamada RE; Crystal RG; Korst RJ
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342
[TBL] [Abstract][Full Text] [Related]
5. Tumor immunology. A neurosurgical perspective. I. General concepts of tumor immunology.
Apuzzo ML; Sheikh KM
Bull Los Angeles Neurol Soc; 1976 Oct; 41(4):168-75. PubMed ID: 1088581
[TBL] [Abstract][Full Text] [Related]
6. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
Jinushi M; Hodi FS; Dranoff G
Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
[TBL] [Abstract][Full Text] [Related]
7. Metastatic spread and "escape" from the immune defenses of the host.
Alexander P
Natl Cancer Inst Monogr; 1976 Nov; 44():125-9. PubMed ID: 1025472
[TBL] [Abstract][Full Text] [Related]
8. A fresh look at tumor immunosurveillance and immunotherapy.
Smyth MJ; Godfrey DI; Trapani JA
Nat Immunol; 2001 Apr; 2(4):293-9. PubMed ID: 11276199
[TBL] [Abstract][Full Text] [Related]
9. Humoral host defense mechanisms against tumors.
Ting CC; Herberman RB
Int Rev Exp Pathol; 1976; 15():93-152. PubMed ID: 176124
[No Abstract] [Full Text] [Related]
10. Mechanisms of tumor-induced immunological deficiencies and their possible significance in relation to the use of immunopotentiators in tumor-bearing hosts.
Kerbel RS
Biomedicine; 1974 Jul; 21(7):253-61. PubMed ID: 4547979
[No Abstract] [Full Text] [Related]
11. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
[TBL] [Abstract][Full Text] [Related]
12. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of Ia antigens.
Crawford RM; Finbloom DS; Ohara J; Paul WE; Meltzer MS
J Immunol; 1987 Jul; 139(1):135-41. PubMed ID: 3108395
[TBL] [Abstract][Full Text] [Related]
13. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
[TBL] [Abstract][Full Text] [Related]
14. Bacteriophages support anti-tumor response initiated by DC-based vaccine against murine transplantable colon carcinoma.
Pajtasz-Piasecka E; Rossowska J; Duś D; Weber-Dabrowska B; Zabłocka A; Górski A
Immunol Lett; 2008 Feb; 116(1):24-32. PubMed ID: 18166233
[TBL] [Abstract][Full Text] [Related]
15. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
16. Concomitant immunization by the fully antigenic counterparts prevents modulated tumor cells from escaping cellular immune elimination.
De Boer RJ; Michelson S; Hogeweg P
J Immunol; 1986 Jun; 136(11):4319-27. PubMed ID: 2939142
[TBL] [Abstract][Full Text] [Related]
17. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
18. [Cancer and immunosuppression : experimental aspects].
Maral J; Florentin I; Soubrane C; Maral R
Bull Cancer; 1983; 70(5):351-71. PubMed ID: 6230125
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of tumor immunity. An overview.
Cohen S; Cohen MC
Am J Pathol; 1978 Nov; 93(2):449-58. PubMed ID: 309731
[TBL] [Abstract][Full Text] [Related]
20. A possible mechanism of tumor regression in cisplatin-treated mice.
Sarna S; Sodhi A; Bhola RK
Pol J Pharmacol Pharm; 1989; 41(1):69-76. PubMed ID: 2587438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
